Literature DB >> 17061296

Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol.

Emilio García Quetglas1, Jose Ramón Azanza, Ernesto Cardenas, Belén Sádaba, Miguel Angel Campanero.   

Abstract

The kinetics of tramadol enantiomers are stereoselective when doses of the racemic drug are given orally. To document whether the route of administration determines the stereoselective kinetics of tramadol enantiomers, healthy volunteers received 100 mg oral or intravenous doses of racemic tramadol, and serial blood samples were obtained to assay tramadol enantiomers and their main phase I metabolites, O-demethyltramadol and N-demethyltramadol. To assess accurately the involvement of their metabolites in the pharmacokinetics of tramadol, it is essential to determine the rate and extent of the formation of the enantiomers of these metabolites. A simultaneous pharmacokinetic model describing the plasma concentration-curves of the generated metabolites and the parent compounds after intravenous and oral drug administration is developed and presented. Tramadol and O-demethyltramadol were the major compounds detected in plasma after intravenous administration. Nevertheless, the N-demethylation of tramadol showed a significant increase when the oral route was used. After both oral and intravenous doses, the kinetics of the tramadol enantiomers were stereoselective. The AUC for (R )-(+)-tramadol was greater than the AUC for (S)-(-)-tramadol. The formation of N-demethyltramadol also was enantioselective after oral administration of racemic tramadol, with a greater AUC for (R)-(+)-N-demethyltramadol than for (S)-(-)-N-demethyltramadol. In the opposite form, (S)-(-)-O-demethyltramadol was formed faster than (R)-(+)-O-demethyltramadol. The metabolism of tramadol was also route-dependent with a different enantiomeric ratio for tramadol and its main phase I metabolites after intravenous and oral administration. The disposition of N-demethyltramadol was concentration-dependent. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17061296     DOI: 10.1002/bdd.526

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  12 in total

1.  Identification of canine cytochrome P-450s (CYPs) metabolizing the tramadol (+)-M1 and (+)-M2 metabolites to the tramadol (+)-M5 metabolite in dog liver microsomes.

Authors:  Tania E Perez Jimenez; Katrina L Mealey; Darren Schnider; Tamara L Grubb; Stephen A Greene; Michael H Court
Journal:  J Vet Pharmacol Ther       Date:  2018-08-16       Impact factor: 1.786

2.  Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.

Authors:  Huybrecht T'jollyn; Jan Snoeys; Pieter Colin; Jan Van Bocxlaer; Pieter Annaert; Filip Cuyckens; An Vermeulen; Achiel Van Peer; Karel Allegaert; Geert Mannens; Koen Boussery
Journal:  Pharm Res       Date:  2014-07-22       Impact factor: 4.200

3.  Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.

Authors:  Huybrecht T'jollyn; Jan Snoeys; An Vermeulen; Robin Michelet; Filip Cuyckens; Geert Mannens; Achiel Van Peer; Pieter Annaert; Karel Allegaert; Jan Van Bocxlaer; Koen Boussery
Journal:  AAPS J       Date:  2015-07-25       Impact factor: 4.009

4.  Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk.

Authors:  Sam Salman; Sherwin K B Sy; Kenneth F Ilett; Madhu Page-Sharp; Michael J Paech
Journal:  Eur J Clin Pharmacol       Date:  2011-03-11       Impact factor: 2.953

5.  Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: Species comparison and identification of responsible canine cytochrome P-450s (CYPs).

Authors:  Tania E Perez Jimenez; Katrina L Mealey; Tamara L Grubb; Stephen A Greene; Michael H Court
Journal:  Drug Metab Dispos       Date:  2016-10-06       Impact factor: 3.922

6.  Pharmacokinetics of tramadol following intravenous and oral administration in male rhesus macaques (Macaca mulatta).

Authors:  K R Kelly; B H Pypendop; K L Christe
Journal:  J Vet Pharmacol Ther       Date:  2014-12-09       Impact factor: 1.786

7.  Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects.

Authors:  Sybil Skinner-Robertson; Caroline Fradette; Sylvie Bouchard; Mohamad-Samer Mouksassi; France Varin
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

8.  Fluorescence detection of tramadol in healthy Chinese volunteers by high-performance liquid chromatography and bioequivalence assessment.

Authors:  Xiao Zhou; Ji Liu
Journal:  Drug Des Devel Ther       Date:  2015-02-26       Impact factor: 4.162

9.  Gender Dependency in Streoselective Pharmacokinetics of Tramadol and Its Phase I Metabolites in Relation to CYP2D6 Phenotype in Iranian Population.

Authors:  Yalda Hosseinzadeh Ardakani; Hoda Lavasani; Mohammad-Reza Rouini
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

10.  Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies.

Authors:  Piotr J Rudzki; Katarzyna Jarus-Dziedzic; Monika Filist; Edyta Gilant; Katarzyna Buś-Kwaśnik; Andrzej Leś; Małgorzata Sasinowska-Motyl; Łukasz Nagraba; Magdalena Bujalska-Zadrożny
Journal:  Pharmacol Rep       Date:  2021-03-08       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.